Revolutionizing Clinical Trials: Castor Secures $45 Million in Series B Funding

We are thrilled to announce that Castor has successfully raised $45 million in our latest funding round, a significant milestone that will propel our mission to revolutionize clinical research through innovative technology. At Castor, we believe in the transformative potential of clinical trials to enhance human healthspan by making them more patient-centered and accessible to everyone, irrespective of geographical barriers. This new capital will enable us to further develop our modular clinical trial platform, which streamlines all aspects of trial management—from recruitment and patient engagement to data collection and results analysis. Each module is designed to operate independently or in conjunction with others, allowing research teams to tailor their approach and scale seamlessly over time. This flexibility ensures a delightful experience for patients while making study management effortless for teams and eliminating risks for sponsors. As we enhance our platform's capabilities, we remain steadfast in our commitment to capturing the world's research data and optimizing every facet of clinical trials. We are excited to use these funds to broaden our reach and refine our technology, ultimately making patient-centered clinical trials a reality for all. Thank you to our investors for their belief in our vision, and to our team for their dedication to this important cause. Together, we are not just advancing clinical research—we're shaping the future of health.